Filing Flows › Comparisons › KROS vs AMRN
Keros Therapeutics vs Amarin: KROS and AMRN compared
Keros Therapeutics is the larger company: $40.0M of revenue in its latest quarter (Q3 2026) against $39.5M for Amarin (Q3 2026). Keros Therapeutics is growing faster (+183% against -20% a year earlier). Keros Therapeutics is more profitable, with an operating margin of 32.0% against -6.0%.
Where the money goes: KROS and AMRN
Keros Therapeutics (KROS) · Q3 2026
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.
Amarin (AMRN) · Q3 2026
Amarin, Q3 2026: revenue $39.5M (-20% year over year), operating margin -6.0%, net earnings $245K, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
| Keros Therapeutics (KROS) | Amarin (AMRN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $40.0M | $39.5M |
| Revenue growth, Y/Y | +183% | -20% |
| Operating margin | 32.0% | -6.0% |
| Net earnings | $14.2M | $245K |
| Net margin | 35.4% | 0.6% |
| Operating cash flow | $3.4M | $9.2M |
| Free cash flow | $3.3M | — |
Where the revenue comes from
Amarin
- Product: $36.9M (93%)
- Licensing and Royalty: $2.7M (7%)
Questions
Which is bigger, Keros Therapeutics or Amarin?
Keros Therapeutics is the larger company: $40.0M of revenue in its latest quarter (Q3 2026) against $39.5M for Amarin (Q3 2026).
Is Keros Therapeutics or Amarin growing faster?
Keros Therapeutics is growing faster (+183% against -20% a year earlier).
Which is more profitable, Keros Therapeutics or Amarin?
Keros Therapeutics is more profitable, with an operating margin of 32.0% against -6.0%.
More: Keros Therapeutics earnings · how Keros Therapeutics makes money · Amarin earnings · how Amarin makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Oct 28, 2026). Fiscal quarters can end on different dates. Not investment advice.